Your browser is no longer supported. Please, upgrade your browser.
Settings
CGTX [NASD]
Cognition Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.45 Insider Own28.10% Shs Outstand22.78M Perf Week-13.63%
Market Cap197.73M Forward P/E- EPS next Y- Insider Trans0.05% Shs Float13.20M Perf Month-28.21%
Income-9.40M PEG- EPS next Q- Inst Own- Short Float0.14% Perf Quarter-
Sales- P/S- EPS this Y-37.80% Inst Trans- Short Ratio0.11 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price24.50 Perf Year-
Cash/sh0.36 P/C23.82 EPS next 5Y- ROE- 52W Range7.95 - 13.80 Perf YTD-32.03%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.10% Beta-
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low9.11% ATR0.97
Employees15 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)24.57 Volatility15.68% 10.12%
OptionableNo Debt/Eq- EPS Q/Q-32.70% Profit Margin- Rel Volume0.36 Prev Close8.27
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume162.88K Price8.68
Recom- SMA20-21.84% SMA50-24.98% SMA200-24.98% Volume58,679 Change4.96%
Nov-03-21Initiated Oppenheimer Outperform $22
Nov-03-21Initiated B. Riley Securities Buy $27
Nov-30-21 07:30AM  
Nov-18-21 08:00AM  
Nov-15-21 07:30AM  
Nov-03-21 08:00AM  
Nov-02-21 06:00AM  
Oct-18-21 10:59AM  
04:37AM  
Oct-15-21 10:26AM  
Oct-12-21 11:23AM  
Oct-08-21 05:50PM  
07:42AM  
07:30AM  
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wallace PeggyDirectorOct 13Buy12.003,00036,0003,000Oct 25 08:18 PM